|
|
Article: Cell Therapeutics, Inc. Receives Orphan Drug Designation for Arsenic Trioxide in the Treatment of Myelodysplastic Syndromes.
- Article from:
- PR Newswire
- Article date:
- July 18, 2000
CopyrightCOPYRIGHT 2000 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FDA Grants Third Orphan Drug Designation for Arsenic TriOxide
SEATTLE, July 18 /PRNewswire/ --
Cell Therapeutics, Inc.'s (cti) (Nasdaq: CTIC) novel cancer drug treatment, Arsenic TriOxide (ATO), has been granted orphan drug designation for the treatment of Myelodysplastic Syndromes (MDS) by the U.S. Food and Drug Administration (FDA).
MDS, also called pre-leukemia or "smoldering" leukemia, are diseases in which the bone marrow does not function normally and not enough normal blood cells are made. MDS may develop following treatment with drugs or radiation therapy for other diseases, or it may develop without any known cause.
An ...